TRACON PHARMS INC - TCON STOCK NEWS

TRACON Pharmaceuticals (NASDAQ: TCON) announced that CEO Charles Theuer will present a corporate overview at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, at 3:10 PM ET. The presentation will focus on TRACON's innovative cancer therapeutics and their cost-efficient, CRO-independent development platform. The company’s pipeline includes Envafolimab for sarcoma, TRC253 for prostate cancer, TRC102 for lung cancer, and TJ004309 for advanced solid tumors. Investors can access the event via the TRACON website.

TRACON Pharmaceuticals (TCON) appointed Lisa Johnson-Pratt, M.D., to its Board of Directors. Johnson-Pratt, previously at Ionis Pharmaceuticals, brings extensive experience in commercializing innovative therapeutics, having worked on products like Gardasil and Singulair. CEO Dr. Charles Theuer highlighted her strategic and operational expertise as crucial for TRACON's mission to develop and potentially commercialize envafolimab in the U.S. in 2023. TRACON continues to focus on targeted cancer therapies with a robust pipeline including envafolimab, TRC253, TRC102, and TJ004309.

TRACON Pharmaceuticals (NASDAQ: TCON) announced that Charles Theuer, M.D., Ph.D., will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. This presentation will be available on-demand starting March 9, 2021, on TRACON's website. The company focuses on developing targeted cancer therapies and has a pipeline that includes Envafolimab for sarcoma, TRC253 for prostate cancer, TRC102 for lung cancer, and TJ004309 for advanced solid tumors. TRACON seeks corporate partnerships to enhance U.S. clinical development and commercialization.

TRACON Pharmaceuticals (NASDAQ:TCON) announced its financial results for Q4 and the full year ended December 31, 2020. The company reported cash reserves of $36.1 million, up from $16.4 million in 2019, expected to fund operations into late 2022. Research and development expenses increased to $2.2 million from $1.9 million year-over-year, while the net loss for Q4 was $4.3 million, slightly up from $4.0 million in 2019. TRACON has launched the ENVASARC trial for envafolimab, with interim data anticipated later this year and commercialization potential in 2023.

TRACON Pharmaceuticals (TCON) will release its fourth quarter and full year 2020 financial results on February 25, 2021, after U.S. markets close. Following the report, management will hold a conference call at 4:30 PM ET to discuss financial and corporate updates. TCON focuses on developing targeted cancer therapeutics using an efficient, CRO-independent platform. Key products in their pipeline include Envafolimab for sarcoma, TRC253 for prostate cancer, TRC102 for lung cancer, and TJ004309 for advanced solid tumors.

TRACON Pharmaceuticals (NASDAQ:TCON) announced that its partners, Alphamab Oncology and 3D Medicines, received priority review for their New Drug Application (NDA) of envafolimab in the treatment of MSI-H/dMMR cancer by the National Medical Products Administration (NMPA) in China. This milestone is significant for potential commercialization. The NDA was initially submitted in November 2020. Envafolimab is also undergoing various registration trials for cancer treatment, including the ENVASARC trial in the U.S., which has recently started dosing patients.

TRACON Pharmaceuticals (NASDAQ: TCON) announced that its CEO, Charles Theuer, will present a corporate overview at the H.C. Wainwright Virtual BioConnect 2021 Conference from January 11-14, 2021. The on-demand presentation will be accessible in the Investors section of the company's website starting January 11. TRACON is focused on developing novel cancer therapeutics and is actively seeking partnerships for U.S. regulatory and clinical development. Its clinical pipeline includes treatments for various cancers, including PD-L1 antibodies and small molecule drugs.

TRACON Pharmaceuticals announced that its partner companies have received notification from the Chinese National Medical Products Administration (NMPA) regarding the acceptance of their new drug application (NDA) for envafolimab in treating MSI-H/dMMR cancer, which includes colorectal and gastric cancer. This milestone reflects significant progress in the drug's clinical development. Envafolimab is also undergoing registration trials in the U.S. and is being tested in various cancer indications.

TRACON Pharmaceuticals (NASDAQ: TCON) announced a securities purchase agreement to sell 520,961 shares of common stock in a registered direct offering at $9.61 per share, totaling approximately $5 million in gross proceeds. This offering is set to close on or about December 30, 2020. The funds will support the ENVASARC pivotal study of envafolimab in sarcoma, business development efforts, and general corporate purposes. The offering is made under an effective shelf registration statement registered with the SEC.